Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP137 + Atezolizumab-Bevacizumab in First-Line Unresectable Hepatocellular Carcinoma
NCT05546879Phase 1Active, not recruiting
- Sponsor
- CHU Grenoble Alpes
- Start
- Mar 2023
- Primary completion
- Mar 2026
- Modality
- Prophylactic Vaccines, IgG Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of np137 in hepatocellular carcinoma (HCC), sponsored by CHU Grenoble Alpes. Primary endpoint: Proportion of patients experiencing adverse events at 36 months. Started Mar 2023; status: active, not recruiting.
02
Drugs
np137
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05546879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05546879.